Table 2

Proportion of patients with ADA to adalimumab at week 26 or last visit, in MTX+ and MTX− groups

ADA-positive
(>12 AU/mL)
ADA-negative
(≤12 AU/mL)
Total
MTX+13 (25.0)39 (75.0)52
MTX−26 (47.3)29 (52.7)55
Total39 (36.4)68 (63.6)107
ADA-high
(>100 AU/mL)
ADA-low
(13–100 AU/mL)
ADA-negative
(≤ 12 AU/mL)
Total
MTX+3 (5.8)14 (26.9)35 (67.3)52
MTX−10 (18.2)19 (34.5)26 (47.3)55
Total13 (12.2)33 (30.8)61 (57.0)107
  • Comparison of ADA+ in MTX+ and MTX− groups: p=0.03

  • ADA, anti-drug antibodies; MTX+, methotrexate+adalimumab; MTX−, adalimumab alone.